162 related articles for article (PubMed ID: 27825418)
1. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
Li R; Xu MJ; Yang FC; Zhou Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
Li W; Xu L
Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
[TBL] [Abstract][Full Text] [Related]
3. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
4. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
5. TET2 in Normal and Malignant Hematopoiesis.
Bowman RL; Levine RL
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
[TBL] [Abstract][Full Text] [Related]
6. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.
Madzo J; Vasanthakumar A; Godley LA
Semin Hematol; 2013 Jan; 50(1):61-9. PubMed ID: 23507484
[TBL] [Abstract][Full Text] [Related]
7. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
8. TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.
Mahfoudhi E; Talhaoui I; Cabagnols X; Della Valle V; Secardin L; Rameau P; Bernard OA; Ishchenko AA; Abbes S; Vainchenker W; Saparbaev M; Plo I
DNA Repair (Amst); 2016 Jul; 43():78-88. PubMed ID: 27289557
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
10. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
11. Role of TET2 mutations in myeloproliferative neoplasms.
Pronier E; Delhommeau F
Curr Hematol Malig Rep; 2012 Mar; 7(1):57-64. PubMed ID: 22200996
[TBL] [Abstract][Full Text] [Related]
12. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.
Kudo Y; Tateishi K; Yamamoto K; Yamamoto S; Asaoka Y; Ijichi H; Nagae G; Yoshida H; Aburatani H; Koike K
Cancer Sci; 2012 Apr; 103(4):670-6. PubMed ID: 22320381
[TBL] [Abstract][Full Text] [Related]
13. Regulation of 5-Hydroxymethylcytosine by TET2 Contributes to Squamous Cell Carcinoma Tumorigenesis.
Boudra R; Woappi Y; Wang D; Xu S; Wells M; Schmults CD; Lian CG; Ramsey MR
J Invest Dermatol; 2022 May; 142(5):1270-1279.e2. PubMed ID: 34695415
[TBL] [Abstract][Full Text] [Related]
14. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H; Kunimoto H
Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
[TBL] [Abstract][Full Text] [Related]
15. Mutations along a TET2 active site scaffold stall oxidation at 5-hydroxymethylcytosine.
Liu MY; Torabifard H; Crawford DJ; DeNizio JE; Cao XJ; Garcia BA; Cisneros GA; Kohli RM
Nat Chem Biol; 2017 Feb; 13(2):181-187. PubMed ID: 27918559
[TBL] [Abstract][Full Text] [Related]
16. [TET2 gene in hematological diseases].
Li S; Wang XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):836-41. PubMed ID: 24989305
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
Pronier E; Almire C; Mokrani H; Vasanthakumar A; Simon A; da Costa Reis Monte Mor B; Massé A; Le Couédic JP; Pendino F; Carbonne B; Larghero J; Ravanat JL; Casadevall N; Bernard OA; Droin N; Solary E; Godley LA; Vainchenker W; Plo I; Delhommeau F
Blood; 2011 Sep; 118(9):2551-5. PubMed ID: 21734233
[TBL] [Abstract][Full Text] [Related]
19. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
20. TET-mediated hydroxymethylcytosine at the Pparγ locus is required for initiation of adipogenic differentiation.
Yoo Y; Park JH; Weigel C; Liesenfeld DB; Weichenhan D; Plass C; Seo DG; Lindroth AM; Park YJ
Int J Obes (Lond); 2017 Apr; 41(4):652-659. PubMed ID: 28100914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
